Drugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss. To give a clearer understanding of the benefits and risks of GLP-1 agonists for patients with liver disease, Robert Fontana, M.D., a Michigan Medicine hepatologist, answered our questions.
Tag: hepatologist
AASLD Foundation Funds Over $1.5 Million in Hepatology Research and Career Development in 2022
The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society supporter of liver disease research and training in the United States, today announced its combined investment of over $1.5 million in Research and Career Development Awards, Abstract Awards, Emerging Liver Scholars (ELS) Program for medical residents and its new Emerging Liver Advanced Practice Provider (APP) Program.
The 2022 award recipients — selected from a highly competitive applicant pool — demonstrate both exceptional aptitude and deep interest in liver disease research and treatment. Their work will further advance the mission of the AASLD Foundation and hepatology as a medical specialty.